Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
J.L. Yov'e come out of retirement.
Same games we've seen before.
To make a long story short. Abbreviated explanation;
The main reason for no competition, patent infringement. Marketing came to a halt after AZN withdrew and does not market the drug. This decision was made during the patent infringement case filed by Amarin. I believe they where ordered to notify Amarin before attempting to market Epanova.
Hasn’t been prescribed to a single patient.
Let me rephrase he gave bad advice. Lol on the options and buyout.
I would say better late then never. But he is seriously late, he missed massive gains.
What about Oppenheimer’s analyst $7 target price - I bet he's the laughing stock around the office. :>)
Good luck J.L. Always considered you as a friend, although one I have never met.
You mean the one for erectile dysfunction?
Hell the share holders have been through the same thing!
These guys have had pretty good timing.
I hate to bring this up, again but selling share seems over board - even for using the excuse of tax liability! There seems to be a bit of greed factor at play while stock holders outside the shpere of insiders, have been patiently awaiting label and sales. I have no problem with rewards. But at least wait until the label is in hand!
J.T.
Ordinary Shares(1)(2) 11/19/2019 S 274,454 D $22.6536(3) 2,342,285(4) D
Before Christmas Holiday break!
"Maybe we've all gotten sturdier sea legs after all this sloppy water."
What kinda sailor talk is this "choppy water."
Let's hope it's not an acquisition!
Market does not seemed phased by $7 dollar target. :>) LMAO.
AMRN, (Trade) has been downgraded by Citigroup as a neutral. Totally clueless as usual.
Sure we’ll be fun! I would like to see positive EPS by next spring hope they turn a profit soon. This is what the market would like to be surprised by.
I followed the Cherry study from Japan for a couple of years. So I will be really excited to see Evaporate results.
Doubt it.
With a 16:0 vote? Very conservative,
But the marketeers are short term thinkers. My 4 year old has a longer attention span!
Great!
Thanks, now we know what the FDA is thinking and what the market will read from this statement.
Look it's about sales after Decembers FDA label decision, you can be sure Physicians will be prescribing for Primary Prevention if Triglycerides are high in middle aged to older population. This is what clinicians will be looking at when prescribing Vascepa.
This is not about primary prevention, but could be both. we will see in December. Remember this vote is not binding, it's up to the FDA.
This AHA meeting this weekend 16-18.
I think J.L. can word primary prevention class better than me. Primary prevention trails are tough, it's about screening people from the population that are at risk for a heart attack. I believe the Jupiter Trail did well because they went after a population with high inflammation, as we should do in the future. Perhaps screening patients for multiple inflammatory markers.
There is no doubt, that this drug would have a positive effect on primary prevention. It's up to the FDA to sort through the data and make a sound scientific decision.
P.S. Why we are excited to see the result of EVAPORATE trial later this week to be made public at the AHA meeting.
O.K. Thanks, well we already knew we were weak in this area by trial design. But a hard look at results and science by the FDA, we should have this added to the label. I'm really curious if EVAPORATE trial results coming in this weekend, added to the mix of trial data to mull over. The FDA may lean toward primary prevention. I think this drug is a preventative medicine and long term damage is cause by leaving EPA/AA ratios unchecked.
SK Please provide some details for us poor souls, who have lost connectivity to FDA ADCOM meeting.
In a good way I hope. Can you provide some detail.
Probably true. I don't think O3's have ever shown any major changes in BP over time.
The other guy was just playing the devils advocate! :>)
Thanks!
Interesting home run report. I had to close my meeting connection. Now hit the limit for connections to FDA meeting. Please give play by play!
Works great, Thanks!
Support for broad label by ADCOM would run the price to $30-35.
Of course the FDA has final say!
And that's just a start!
Once we receive approved label changes, the FDA for the most part will be out of the loop. It will be sales/revenue driven stock.
After that the risk vs reward improves.
Tooooo late for him!
That is good new and about time, I had UHC two months ago but we recently switched to Cigna PR/Virgin Islands Vascepa copay $100. I missed I missed BC/BS they were $40 copay.
"ADCOM May or may not know about evaporate embargoed results."
Thanks for the info, I was wondering about the reason for EVAPERATE's delayed results. So I'm assuming it will be presented at AHA meeting mid November. No doubt Vascepa plaque reduction played a role in 35% less revascularization, this is an eye opener.
Well it's important for investors to know this tidbit of information. I'm confident ADCOM will go well and Amarin will be very prepared. The deciding vote will be on the FDA. I don't think things would go well for the FDA, if they voted against any form of label expansion. Since they got the thumbs up by the AHA and ADA.
I think this will be more about, how broad the label will be.